SELLAS Life Sciences Group, Inc. (SLS) announced on Monday further data from the expansion cohorts in their Phase 2 trial targeting relapsed/refractory acute myeloid leukemia with their SLS009 treatment.
This open-label, single-arm, multi-center study assessed the safety, tolerability, and efficacy of SLS009 when combined with venetoclax and azacitidine, tested at two dosage levels of 45 mg and 60 mg. Participants receiving the 60 mg dose were randomly assigned to either a weekly 60 mg dose or a twice-weekly 30 mg dose.
Results indicated that for the cohort receiving the twice-weekly 30 mg dosage, the median overall survival rate has surpassed 7.7 months, which is significantly higher than the historically expected median overall survival of approximately 2.5 months.
Moreover, among patients with acute myeloid leukemia exhibiting myelodysplasia-related changes who were enrolled in two expansion cohorts, the overall response rate achieved was 56%, surpassing the predetermined target response rate of 33%.
Meanwhile, on the Nasdaq, SELLAS's stock is experiencing a decline of 1.75%, currently priced at $1.13.
